First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
UCB plans to submit regulatory applications in Q3 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Subscribe To Our Newsletter & Stay Updated
